ABSTRACT
Background:
The KCNMA1 gene encodes the α-subunit of the large conductance, voltage, and calcium-sensitive potassium channel (BK channels) that plays a critical role in neuronal excitability. Heterozygous mutations in KCNMA1 were first illustrated in a large family with generalized epilepsy and paroxysmal nonkinesigenic dyskinesia. Recent research has established homozygous KCNMA1 mutations accountable for the phenotype of cerebellar atrophy, developmental delay, and seizures.
Case Report:
Here, we report the case of a patient with a novel homozygous truncating mutation in KCNMA1 (p.Arg458Ter) presenting with both the loss- and gain-of-function phenotype with paroxysmal dyskinesia, epilepsy, intellectual delay, and corticospinal–cerebellar tract atrophy.
Conclusion:
This report extends the KNCMA1 mutation phenotype with a patient who carries a novel frameshift variant, presenting with both the gain- and loss-of-function phenotypes along with spinal tract involvement as a novel characteristic.
The KCNMA1 gene encodes the a-subunit of the large conductance, voltage, and calcium-sensitive potassium channel (BK channels), which is also activated by the concentration of cytosolic Mg2+ and is known to be predominantly expressed in the amygdala, caudate nucleus, cerebral cortex, hippocampus, hypothalamus, spinal cord, and Purkinje cells in the cerebellum (1,2). Initially, the KCNMA1 mutations were illustrated in a large family with generalized epilepsy and paroxysmal nonkinesigenic dyskinesia (3). A recent study established a correlation of the homozygous KCNMA1 mutation with cerebellar ataxia, developmental delay, and seizures. In addition, both the gain- and loss-of-function have been proposed as the underlying molecular mechanism in this channelopathy resulting in increased excitability (4). Here, we report the case of a patient with a novel homozygous truncating mutation in KCNMA1 (p.Arg458Ter) presenting with both the loss- and gain-of-function phenotype with paroxysmal dyskinesia, epilepsy, intellectual delay, and corticospinal–cerebellar tract atrophy.
CASE PRESENTATION
A 15-year and 11-month-old male patient was referred to our genetics unit at the age of 15 years. He was born at term to a third-degree consanguineous healthy parents with a healthy birth weight (3250 g), height (53 cm), and occipitofrontal circumference (34 cm). There was a prolonged labour, and the APGAR score was 7-8. His motor milestones were delayed, and he never walked alone. In addition, he had a social smile and could talk approximately 10 simple words. His seizures, although mostly absent, started at the age of 18 months and were well-controlled by valproic acid. Meanwhile, he also experienced clonic and generalized tonic–clonic (GTCS) and atonic seizures and had spasticity predominant in the lower extremities with no pathological reflexes. While electroencephalography revealed generalized spike-wave activities, electromyography and metabolic tests were normal. Furthermore, the brain magnetic resonance imaging (MRI) performed at the age of 3 years revealed moderate atrophy with prominent folia in the upper parts of the supratentorial cerebellar vermian region. Moreover, symmetric T2 hyperintensities were observed at the retroatrial periventricular deep white matter. Diffusion tensor imaging images obtained at the age 14 years revealed the involvement of tegmental to corticospinal atrophy (Figure 1). Besides, the atrophy of the cerebellum had progressed compared to previous MRI studies (Figure 2). The patient’s last examination determined contractures on the large joints, dyskinetic tremor, and dystonia. Of note, this study was reported per the tenets of the Declaration of Helsinki and was approved by the institutional review board and ethical committee of our university. We obtained written informed consent from the patient.
The exome sequencing revealed a homozygous nonsense change in the KCNMA1 gene NM_001161352.1:c.1372[C>T];[C>T] NP_001154824.1:p.[(Arg458*)];[(Arg458*)]. The variant was not observed in any publicly available database (e.g., EXAC, EVS, and 1000 genomes) or in our internal database. In addition, we identified another variant, rs60734921, in the CACNAH1 gene, which has been described in a study as a risk factor for generalized idiopathic epilepsy (5). While the population frequency of the variant in the CACNAH1 gene was 0.0012/39 according to the EXAC, it was classified as a variant of unknown significance in the dbSNP database (Table 2).
DISCUSSION
Large-conductance calcium-sensitive BK channels are one of the potassium channels that hyperpolarize the neurons and are encoded by KCNMA1 (6,7). Reportedly, mutations in KCNMA1 have been identified in clinical cases of epilepsy and paroxysmal nonkinesic dyskinesia (3,8). In addition, a study functionally investigated the D434G mutation of KCNMA1 by the patch clamp method and was found to be associated with the gain of function (3). Some studies have suggested that the gain of function at BK channels resulted in the faster and rapid repolarization of the action potential in the syndrome mechanism, accounting for an increase in the excitability of the brain (3,9). Moreover, Sausbier et al. (2,10) reported that KCNMA1-/- mice exhibited abnormal eye-blink reflex, abnormal locomotion, and abnormal motor coordination. Thus, either gain- or loss-of-function mutations might result in the disease phenotype. Furthermore, both the gain- and loss-of-function phenotype can be observed in other channelopathies such as KCNA2, GRIN1, and DEAF1 gene mutations.
Recently, Tabarki et al. (4) reported a different phenotype of the same gene. In their study, the siblings were homozygous for a frameshift variant in KCNMA1 and had tractable myoclonic seizures starting around the age 1, which later evolved into tonic and GTCS type. In addition, they had a severe developmental delay, but no dyskinesia, and their brain MRI revealed cerebellar atrophy that was not a feature of previously reported heterozygous mutations (4). Table 1 summarizes the clinical and characteristic features of patients with KCNMA1 mutations. Unlike previous reports, our case had corticospinal and tegmental tract involvement besides cerebellar atrophy, which could be attributed to the possible progressive course of the disease attributive to the advanced age of our patient. In addition, our patient had dyskinesia and dystonic movements, which were not known for biallelic mutations. Reportedly, the variant found in the CACNA1H gene could also contribute the proband’s phenotype; however, the variant is a known single nucleotide polymorphism that was considered a risk factor for generalized epilepsy but not the dyskinesia phenotype (5).
In conclusion, this report presents a unique case of a patient who manifested both phenotypes of the gain- and loss-of-function mutations of KCNMA1 (dyskinesia, epilepsy, and cerebellar atrophy) and had tegmental and spinal tract atrophy that has not been reported to date. Thus, electrophysiological analyses and expression studies are warranted to gain an insight into functional consequences of biallelic mutations of the KCNMA1 gene. Overall, this study highlights the importance of using exome sequencing techniques for expanding the disease phenotypes to reveal the disease pathogenesis.